MRSI to Predict Response to RT/TMZ ± Belinostat in GBM

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

29 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-05-07

Study Completion Date

2024-08-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the first phase of this study (Cohort 1), the investigators will determine the feasibility of adding MRSI to the evaluation of newly-diagnosed GBM patients treated with standard RT/TMZ and determine whether magnetic resonance spectroscopic imaging (MRSI) can predict for better outcomes in these patients. In the second phase of this study (Cohorts 2a and 2b), the investigators will find the maximum tolerated dose of belinostat for treating newly-diagnosed GBM patients with standard RT/TMZ and will determine whether MRSI can aid clinicians in the early determination of response to this new therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma

NCT03137888

Glioblastoma Gliosarcoma

COMPLETED PHASE2

Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma

NCT04574856

Glioblastoma

ACTIVE_NOT_RECRUITING PHASE2

An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

NCT02667587

Brain Neoplasms

COMPLETED PHASE3

Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme

NCT01822275

Histologically Proven Diagnosis of Glioblastoma or Gliosarcoma (WHO Grade IV)

TERMINATED PHASE2

Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma Multiforme

NCT00238277

Brain and Central Nervous System Tumors

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients will be assigned to Cohort 1 (standard RT/TMZ) followed by entry to either Cohort 1 or Cohort 2a (standard RT/TMZ + dose finding for belinostat), followed by assignment to Cohort 2b (standard RT/TMZ + tolerable dose of belinostat).

Patients will undergo MRSI scans before beginning treatment and then at several time points during treatment to look for the early response of their tumor to treatment. Blood and tumor samples will be used to measure the levels of certain markers within the cancer cells. Patients will also be assessed for the side effects they experience. Progression-free and overall survival outcomes will be recorded. Patients will also have assessment of their depressive symptoms, quality-of-life and neurocognitive function at several time points during and after therapy course.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioblastoma Multiforme of Brain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Std RT/TMZ (Cohort 1)

* Standard radiation therapy
* Standard temozolomide

Group Type ACTIVE_COMPARATOR

Standard Radiation Therapy

Intervention Type RADIATION

Radiation therapy to 60 Gy

Standard Temozolomide

Intervention Type DRUG

Temozolomide given orally

Std RT/TMZ + belinostat (Cohorts 2a, 2b)

* Standard radiation therapy
* Standard temozolomide
* Belinostat

Group Type EXPERIMENTAL

Standard Radiation Therapy

Intervention Type RADIATION

Radiation therapy to 60 Gy

Standard Temozolomide

Intervention Type DRUG

Temozolomide given orally

Belinostat

Intervention Type DRUG

Belinostat dose to be determined, given intravenously over 30-45 minutes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standard Radiation Therapy

Radiation therapy to 60 Gy

Intervention Type RADIATION

Standard Temozolomide

Temozolomide given orally

Intervention Type DRUG

Belinostat

Belinostat dose to be determined, given intravenously over 30-45 minutes

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Temodar Beleodaq PXD101

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Newly-diagnosed glioblastoma or gliosarcoma that has been confirmed pathologically
* ≥ 18 years of age
* Able to have MRI scans
* Measurable contrast-enhancing supratentorial tumor (≥ 0.2 cc (current resolution of MRSI is 0.108cc)) in a region amenable to MRSI
* Have the following lab values ≤ 14 days prior to registration:

* white blood cell count ≥ 3,000/μL
* absolute neutrophil count ≥ 1,500/μL
* platelet count of ≥ 100,000/μL
* hemoglobin ≥ 10 gm/dL (transfusion is allowed to reach minimum level)
* serum glutamic-oxaloacetic transaminase (SGOT) ≤ 2.0x upper normal limit (UNL)
* bilirubin ≤ 2 x UNL
* creatinine ≤ 1.5 mg/dL
* Life expectancy of ≥ 12 weeks
* Karnofsky Performance Score ≥ 60
* Women of childbearing potential must have a negative beta-human chorionic gonadotropin pregnancy test documented ≤ 7 days prior to registration
* All men and women of childbearing potential must agree to use adequate barrier contraception for the duration of study participation and for 12 weeks after the last dose of study drug (If pregnancy or suspected pregnancy occur while participating in study, treating physician should be informed immediately)
* Understand and provide written informed consent
* Both men and women, and members of all races and ethnic groups are eligible for this trial (Subjects will be approximately representative of the demographics of the referral base for the participating institutions)
* Able to swallow capsules
* Willing to provide mandatory tissue samples (unstained slides) for research purposes
* Willing to forego other cytotoxic and non-cytotoxic therapies against the tumor while being treated on this protocol

Exclusion Criteria

* Pacemakers, non-titanium aneurysm clips, neurostimulators, cochlear implants, non-titanium metal in ocular structures, history of being a steel worker, or other incompatible implants which makes MRI safety an issue
* Any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy
* History of any other invasive cancer (except non-melanoma skin cancer and excluding carcinoma in-situ), unless in complete remission and off of all therapy for that disease for ≥ 3 years, are ineligible
* Active infection or serious intercurrent medical illness
* Any disease that will obscure toxicity or dangerously alter drug metabolism
* Receiving any other investigational agents
* Received prior cytotoxic, non-cytotoxic or experimental drug therapies for brain tumor
* History of prior cranial radiation
* History of myocardial infarction or unstable angina ≤ 6 months prior to registration or congestive heart failure (CHF) requiring use of ongoing maintenance therapy, or life-threatening ventricular arrhythmias
* Patients with congenital long QT syndrome (for cohorts 2a and 2b \[belinostat cohorts\] only, ECG not required for cohort 1)
* Has prolonged corrected QT (QTc) interval (\> 450 msec) (for cohorts 2a and 2b \[belinostat cohorts\] only, ECG not required for cohort 1)
* Taking any of the following Category I drugs that are generally accepted to have a risk of causing Torsades de Pointes ≤ 7 days prior to registration (for cohorts 2a and 2b \[belinostat cohorts\] only)

* Quinidine, procainamide, disopyramide
* Amiodarone, sotalol, ibutilide, dofetilide
* Erythromycin, clarithromycin
* Chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide
* Cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine
* Taking valproic acid ≤ 2 weeks prior to initiation of belinostat therapy (for cohorts 2a and 2b \[belinostat cohorts\] only)
* May not be enrolled on any other therapeutic trial for which they are receiving an anti-tumor therapy. (Note: patients on the standard therapy arm of another GBM trial that otherwise meet eligibility requirements for this trial remain eligible for cohort 1)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No